ライフサイエンスコーパス: SIRT1

1 SIRT1 co-localizes with BCL6 in the nuclei of affected i

2 SIRT1 deacetylates S6K1, thereby enhancing its phosphory

3 SIRT1 deficiency in the epidermis inhibited the regenera

4 SIRT1 function is aberrantly low in obesity, so understa

5 SIRT1 has emerged as an attractive therapeutic target fo

6 SIRT1 iKO mice also had altered fecal microbiota startin

7 SIRT1 is critical for OGT-mediated regulation of FOXM1 u

8 SIRT1 is part of the E1-E2 DNA replication complex and i

9 SIRT1 is the proto member of the proteins in the mammali

10 SIRT1 loss altered the production of many cytokines, inh

11 SIRT1 might therefore be an important mediator of host-m

12 SIRT1 mRNA and protein decreased significantly in both c

13 SIRT1 phosphorylation also facilitates replication fork

14 SIRT1 regulates Dishevelled (DVL) protein levels in canc

15 SIRT1 substrates include histones and proteins related t

16 SIRT1 T530 phosphorylation is essential to prevent DNA b

17 SIRT1, the founding member of the mammalian family of se

18 SIRT1, the most conserved mammalian NAD(+)-dependent pro

19 SIRT1-mediated signalling through Akt, the endothelial n

20 SIRT1-regulated Akt, endothelial nitric oxide synthase a

21 ing type information regulation 2 homolog 1 (SIRT1), which deacetylates forkhead box o3 (FOXO3a), lea

22 g type information regulation 2 homologue 1 (SIRT1) activity and content increased significantly in o

23 g type information regulation 2 homologue 1 (SIRT1) content and activity (P < 0.001).

24 wn regulated silent information regulator 1 (SIRT1), a class-III histone deacetylase (HDAC), resultin

25 vo Mammalian silent information regulator 1 (SIRT1), a NAD(+)-dependent histone deacetylase, is an im

26 HES1) and the protein deacetylase sirtuin 1 (SIRT1) at the Isl1 gene.

27 gher abundance of the deacetylase sirtuin 1 (SIRT1) correlated with lower acetylation occupancy and l

28 l activation that the deacetylase Sirtuin 1 (SIRT1) has an anti-inflammatory role in a less severe, T

29 (+)-dependent lysine deacetylase, sirtuin 1 (SIRT1) in fibrogenesis in the cell culture, animal model

30 e sought to determine the role of sirtuin 1 (SIRT1) in skin barrier function, FLG expression, and dev

31 Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent

32 Sirtuin 1 (SIRT1) is an NAD(+)-dependent deacetylase that functions

33 Sirtuin 1 (SIRT1) is involved in both aging and circadian-clock reg

34 We investigated how Sirtuin 1 (SIRT1), a conserved mammalian NAD(+)-dependent protein d

35 on of KRAS and over-expression of Sirtuin 1 (SIRT1), a histone deacetylase and gene silencer, in the

36 (+)-dependent protein deacetylase sirtuin 1 (SIRT1), a key regulator of mammalian metabolism, maintai

37 wn interaction in transactivating Sirtuin 1 (SIRT1), a NAD(+)-dependent histone deacetylase that medi

38 Sirtuin 1 (SIRT1), an NAD(+)-dependent deacetylase, has been associ

39 ty acid beta-oxidation, including sirtuin 1 (SIRT1), sirtuin 3 (SIRT3), and Nrf-1.

40 Sirtuin 1 (SIRT1), the founding member of Class III histone deacety

41 the NAD(+)-dependent deacetylase sirtuin 1 (SIRT1).

42 role in OLT and interactions with sirtuin-1 (SIRT1), a key autophagy regulator, have not been studied

43 apy, by reversing the expression of miR-34a, SIRT1, cyclin D1, and E-cadherin.

44 We observed that both sirtuins 1 and 7 (SIRT1 and SIRT7) are able to deacetylate FOXO3 in vitro

45 (9), an AMPK inhibitor, or of EX-527 (10), a SIRT1 inhibitor, highlighting the involvement of the SIR

46 Conversely, intra-NAc infusions of EX-527, a SIRT1 antagonist, reduced these behaviors; EX-527 also r

47 entified the transcription factor FoxO1 as a SIRT1 target involved in transcriptional reprogramming o

48 anwhile, SIRT1 induction or treatment with a SIRT1 agonist, resveratrol, inhibits AR-stimulated proli

49 The results showed that DLA could activate SIRT1 after I/R probably by binding to this protein, dep

50 Agents designed to activate SIRT1 might be developed as treatments for IBDs.

51 ckdown of PGC1alpha, its essential activator SIRT1, or its binding partner/co-activator EP300 inhibit

52 he periphery, maintaining full-length active SIRT1 protein.

53 s is linked to subnuclear dynamics of active SIRT1.

54 rrelation between SIRT1 levels and activity, SIRT1-regulated pathways and overload-induced hypertroph

55 tiation factor RRN3, were up-regulated after SIRT1 inhibition.

56 ssion in this brain region and that altering SIRT1 activity using a pharmacological or genetic approa

57 metabolism to invasion and metastasis via an SIRT1/ERK/FOXM1 axis.

58 ranscriptional complexes with PGC-1alpha and SIRT1 in the nucleus.

59 ivity, possibly by activating PGC-1alpha and SIRT1, to improve physical endurance, strongly suggestin

60 en NAD(+) metabolism, NADH distribution, and SIRT1 activity in the nucleus of live cells and pave the

61 e also induced in hypertrophied muscles, and SIRT1 levels correlated with muscle mass, paired box pro

62 rase 2a (MAT2a), is under control of Myc and SIRT1.

63 on its canonical targets such as Notch1 and SIRT1, and on Ras/MAPK-dependent pathways.

64 with significant effects for MTF2, PHF19 and SIRT1 (P<0.05).

65 in untreated PMDD LCLs with MTF2, PHF19 and SIRT1 all significantly decreased (P<0.05).

66 ulin sensitivity (ADIPOQ, GLUT4, PPARG2, and SIRT1) and lipogenesis (SREBP1c, ACC, LPL, and FASN).

67 Two h of PTH treatment augmented SIRT1 association with c-Jun, a component of the transcr

68 proliferation phenotype are also found to be SIRT1-dependent in proliferating mouse embryonic fibrobl

69 nsible for promoting tighter binding between SIRT1 and the peptide and the stimulation of SIRT1 activ

70 results reveal a strong correlation between SIRT1 levels and activity, SIRT1-regulated pathways and

71 his negative reciprocal relationship between SIRT1 and PER2 was also observed in human hepatocytes.

72 Reducing both SIRT1 and c-Myc expression in 3T3-L1 cells simultaneousl

73 f tumor metabolism and possibly apoptosis by SIRT1 mechanistically contribute to the observed dual ro

74 shown to be prone to hydrolytic cleavage by SIRT1-3 and SIRT6, supporting recent findings.

75 pression, and this regulation is mediated by SIRT1 association with c-Jun at the AP-1 site of the Mmp

76 bitor nicotinamide are primarily mediated by SIRT1 inhibition.

77 diated MMP13 gene expression is repressed by SIRT1 in human chondrocytes.

78 nt with the SIRT1 inhibitor EX-527 confirmed SIRT1's role in the regulation of pre-rRNA synthesis and

79 From 346 experimentally confirmed SIRT1 inhibitors, an inhibitor structure pattern was gen

80 e data identify the evolutionarily conserved SIRT1-FoxO1 axis as a regulator of resting CD8(+) memory

81 Consistently, SIRT1 KO embryos display reduced Mat2a expression and hi

82 ent as part of a cocktail provided continued SIRT1 activity elevation is achieved.

83 of methyltransferase DNMT3b and deacetylase SIRT1 may explain the observed p66(Shc)-related epigenet

84 ine dinucleotide (NAD)-dependent deacetylase SIRT1 acts as an energy sensor and negatively regulates

85 ependent on the NAD(+)-dependent deacetylase SIRT1.

86 scade involving AMPK and histone deacetylase SIRT1 displaces chromatin-bound BRD4, instigating autoph

87 on is regulated by the class III deacetylase SIRT1; activation of the DNA damage response prevents SI

88 of the NAD(+)-dependent protein deacetylase SIRT1.

89 new partner that we define, the deacetylase SIRT1.

90 d circadian phase advancements by decreasing SIRT1 activity through competition for NAD supplies.

91 We reported that NAD(+)-dependent SIRT1, RELB, and SIRT6 nuclear proteins in monocytes reg

92 Remarkably, differentiating SIRT1-silenced preadipocytes exhibit enhanced mitotic cl

93 STACs (represented by resveratrol) as direct SIRT1 activators is under debate due to the complication

94 Moreover, AMPK-directed SIRT1 phosphorylation is required for energy starvation-

95 alpha co-activator function by disinhibiting SIRT1 deacetylase activity.

96 therapeutic relevance of targeting duodenal SIRT1 to reverse insulin resistance and improve glucose

97 atic activity decreased significantly during SIRT1 overexpression or activation by resveratrol.

98 robably due to a failure to sustain elevated SIRT1 activity and downstream PGC-1alpha signalling.

99 Reducing O-GlcNAcylation elevates SIRT1 levels and activity in an AMPK (AMP-activated prot

100 eserved hepatocellular function and enhanced SIRT1/LC3B expression.

101 report demonstrates that a cellular enzyme, SIRT1, is part of the HPV16 DNA replication complex and

102 d activity through the regulation of the EP1/SIRT1 pathway.

103 c mouse model, we demonstrate that epidermal SIRT1 plays a crucial role in wound repair.

104 kin lesions in mice, and mice with epidermal SIRT1 deletion are sensitive to percutaneous challenge b

105 1 specifically in the intestinal epithelium (SIRT1 iKO, villin-Cre+, Sirt1(flox/flox) mice) and contr

106 is a negative regulator of MMP13 expression, SIRT1 activation inhibits PTH stimulation of Mmp13 expre

107 e, as well as to analyze the requirement for SIRT1 in autophagy regulation by HO-1.

108 , -7.8, and -8.6 kcal/mol, respectively) for SIRT1 as estimated by molecular docking software AutoDoc

109 eacetylation, suggesting a possible role for SIRT1 activators in cancer therapy.

110 his study, we demonstrate a pivotal role for SIRT1 in anxiety- and depression-like behaviors in the n

111 hers have demonstrated an essential role for SIRT1 in regulation of the HPV31 life cycle; here, we re

112 Intestinal tissues from SIRT1 iKO mice given antibiotics, however, did not have

113 Furthermore, SIRT1 reduction, but not deletion, is associated with hu

114 of liver proliferation C/EBPalpha, p53, FXR, SIRT1, PGC1alpha, and TERT by C/EBPbeta-HDAC1 complexes.

115 upon replication stress and cells harboring SIRT1 that cannot be phosphorylated exhibit a high preva

116 In cultured primary human hepatocytes, SIRT1 messenger RNA was down-regulated after GCA treatme

117 cked Isl1 suppression via the HIF1alpha/HES1/SIRT1 complex and prevented CHDs induced by pathological

118 resveratrol exhibited increased hippocampal SIRT1 activity and preserved hippocampus-dependent memor

119 h-fat diet-mediated reduction of hippocampal SIRT1 could be responsible for obesity-linked memory imp

120 aches strongly implicate reduced hippocampal SIRT1 as being a principal pathogenic mediator of obesit

121 D(+) levels regulate SIRT1 activity, but how SIRT1 enzymatic activity impacts on NAD(+) levels and it

122 re known to augment Rac activation; however, SIRT1 or 2 has not been previously linked with TIAM1.

123 We report that phosphorylation of the human SIRT1 deacetylase on Threonine 530 (T530-pSIRT1) modulat

124 evance of HO-1 cytoprotection and identifies SIRT1-mediated autophagy pathway as a new essential regu

125 Taken together, this work identifies SIRT1 as a critical node that links beta-adrenergic sign

126 Similar changes in SIRT1, phosphatase and tensin homolog, and Akt were also

127 FoxO1 is proteasomally degraded in SIRT1-deficient CD8(+)CD28(-) T cells, and inhibiting it

128 llating genes under CR show an enrichment in SIRT1 targets in the liver.

129 s, which will have important implications in SIRT1-small-molecule-activator/inhibitor-based therapeut

130 FOXO1 was directly linked to an increase in SIRT1-MTORC2 interaction and RICTOR deacetylation.

131 Increases in SIRT1, a well characterized class III histone deacetylas

132 t the importance of methionine metabolism in SIRT1-mediated mESC maintenance and embryonic developmen

133 s altered to drive enhanced proliferation in SIRT1-silenced 3T3-L1 cells.

134 o the human setting, we noted a reduction in SIRT1 mRNA in kidney biopsies obtained from individuals

135 ed as a major serine phosphorylation site in SIRT1 in obese, but not lean, mice, and this phosphoryla

136 evels of many miR-34a target genes including SIRT1, BCL2, c-MET, and CDK6.

137 respond to various human sirtuins, including SIRT1, SIRT2, SIRT3 and SIRT5.

138 aristoforin were able to inhibit or increase SIRT1 catalytic activity, depending on protein concentra

139 panied by decreased OLT damage and increased SIRT1/LC3B expression, whereas adjunctive inhibition of

140 procedure, some of them displayed increased SIRT1 activation with respect to the prototype 3a, high

141 AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC pro

142 Next, we increased SIRT1 levels directly in NAc by use of viral-mediated ge

143 dated model of depression in mice, increases SIRT1 levels in the nucleus accumbens (NAc), a key brain

144 a, whereas tauroursodeoxycholic acid induced SIRT1 expression without affecting miR-34a expression.

145 Furthermore, pharmacologically induced SIRT1-mediated deacetylation can attenuate aberrant NEDD

146 We show that stress stably induces SIRT1 expression in this brain region and that altering

147 LEF1-beta-catenin interaction by inhibiting SIRT1-mediated beta-catenin deacetylation, thereby enhan

148 strate that an enzyme with known inhibitors, SIRT1, plays an important role in controlling how HPV16

149 rkhead box O 1 and protein ubiquitination is SIRT1 dependent.

150 In keratinocytes, SIRT1 knockdown inhibited EMT, cell migration, and TGF-b

151 Together, these data suggest that KRAS, SIRT1 and BCL6 are coordinately over-expressed in eutopi

152 In the liver, SIRT1 coordinates the circadian oscillation of clock-con

153 les and TCGA database, which showed that low SIRT1 gene expression in tumor tissues compared with nor

154 PBMs from healthy controls had lower SIRT1 and SIRT7 and readily formed p-FOXO3 and underwent

155 y and negatively correlate with muscle mass, SIRT1 and Nampt levels.

156 Meanwhile, SIRT1 induction or treatment with a SIRT1 agonist, resve

157 We also directly monitored SIRT1 and SIRT2 activity in HEK293T cells with an mCherr

158 Moreover, SIRT1 iKO mice with defective gut microbiota developed m

159 Moreover, SIRT1 is required for the induction of PGC-1alpha/PPAR-a

160 d mitochondrial function via the PARP-NAD(+)-SIRT1-PGC1alpha axis.

161 otinamide phosphoribosyltransferase (NAMPT), SIRT1 activity and phosphorylation of AMPK; (3) up-regul

162 Conversely, selective ablation of SIRT1 in the NAc using viral-Cre in floxed Sirt1 mice re

163 ion was significantly affected by absence of SIRT1 in the liver, as well as circadian gene expression

164 lization of the E2 protein in the absence of SIRT1.

165 bited expression of AR through activation of SIRT1 in breast cancer cells.

166 rthermore, the pharmacological activation of SIRT1 with resveratrol significantly reduces motor incoo

167 ial health benefit through the activation of SIRT1, a crucial member of the mammalian NAD(+)-dependen

168 resveratrol, a pharmacological activator of SIRT1, was directly infused bilaterally into the NAc, we

169 apoptotic form of FOXO3 and the activity of SIRT1 and particularly SIRT7 regulate this process in vi

170 ditional step toward the characterization of SIRT1 function in the liver.

171 lization of a repressive complex composed of SIRT1 and the H3K9 methyltransferase SUV39H1, thereby ma

172 34a accompanied with significant decrease of SIRT1 and nicotinamide phosphoribosyltransferase (NAMPT)

173 Mice with intestinal deletion of SIRT1 (SIRT1 iKO) had abnormal activation of Paneth cell

174 ice with intestinal epithelial disruption of SIRT1, we found this protein to prevent intestinal infla

175 mediated by neuroepigenetic dysregulation of SIRT1 within the hippocampus.

176 In addition, the re-establishment of SIRT1 levels in MJD mouse model, through the gene delive

177 Evidence of SIRT1-RELB induction of mitochondrial biogenesis include

178 ty, low endogenous NAD(+), low expression of SIRT1 and PGC1alpha and low adenosine monophosphate (AMP

179 ic hepatitis patients had high expression of SIRT1 and SIRT7 and failed to induce p-FOXO3 and apoptos

180 ncer patients with low protein expression of SIRT1 have a poor prognosis.

181 ovirus-mediated liver-specific expression of SIRT1 or a phosphor-defective S164A-SIRT1 mutant promote

182 e gene dosage-dependent in vivo functions of SIRT1 in skin tumorigenesis and may shed light on the ro

183 evealed for the first time the importance of SIRT1 in the regulation of hepatocellular proliferation,

184 the PGR positive cells reveal an increase of SIRT1 expression in the endometrium compared to control

185 expression, whereas adjunctive inhibition of SIRT1 signaling diminished HO-1-mediated hepatoprotectio

186 rbs identified 12 compounds as inhibitors of SIRT1.

187 th undetectable SIRT1 expression and lack of SIRT1 elevated E1-E2 DNA replication, in part due to inc

188 nt increased both mRNA and protein levels of SIRT1 in podocytes and that puerarin led to SIRT1-mediat

189 itis expressed significantly lower levels of SIRT1 mRNA than controls.

190 ion in HMECs correlate with misregulation of SIRT1 leading to increased levels of acetylated pRb as w

191 gene expression; however, overexpression of SIRT1 during IL-1beta challenge impeded LEF1 levels and

192 Mechanistically, phosphorylation of SIRT1 at Ser-164 substantially inhibited its nuclear loc

193 Thus, inhibition of phosphorylation of SIRT1 by CK2 may serve as a new therapeutic approach for

194 show that obesity-linked phosphorylation of SIRT1 inhibits its function and promotes pathological sy

195 , and SIRT6 reveals that the acyl pockets of SIRT1-3 are highly similar, and to a lesser degree, simi

196 her these studies highlight the potential of SIRT1 activation as a therapeutic strategy in progressiv

197 recently reported as a negative regulator of SIRT1 and a transcriptional coactivator, in the regulati

198 origenesis and may shed light on the role of SIRT1 in epithelial cancer induced by DNA damage.

199 In this study, we assessed the role of SIRT1 in LEF1-mediated MMP13 gene expression in human OA

200 However, the role of SIRT1 in the multi-step process leading to transformatio

201 h SIRT1 activity is altered, and the role of SIRT1 in tumor metabolism is unknown.

202 lly contribute to the observed dual roles of SIRT1 in tumorigenesis.

203 SIRT1 and the peptide and the stimulation of SIRT1 activity.

204 ol toward some "loose-binding" substrates of SIRT1, and has significant implications for the rational

205 FOXO3 acetylation, partly by suppression of SIRT1 and SIRT7.

206 ne supplementation increases the survival of SIRT1 KO newborn mice.

207 mitochondria and unexpectedly is a target of SIRT1 deacetylation.

208 parison of the SIRT2 acyl pocket to those of SIRT1, SIRT3, and SIRT6 reveals that the acyl pockets of

209 Ubiquitination of SIRT1 affected its function in cell death and survival i

210 lex 1 (mTORC1) signaling and upregulation of SIRT1 activity with associated health benefits.

211 , and its subnuclear distribution depends on SIRT1.

212 Deacetylation of FOXO3 by SIRT activation or SIRT1 or SIRT7 overexpression prevented its S574 phospho

213 inst SIRT2 and high isozyme selectivity over SIRT1 and SIRT3.

214 inducible viral vector system to overexpress SIRT1 selectively in dopamine D1 or D2 subpopulations of

215 required for energy starvation-induced PABP1-SIRT1 association, PABP1 deacetylation, and poly(A)RNA n

216 The pharmacological SIRT1 activation could provide important benefits to tre

217 tivation of the DNA damage response prevents SIRT1 deacetylation of TopBP1, resulting in a switch fro

218 ex, activator protein 1 (AP-1), and promoted SIRT1 association with the AP-1 site of the Mmp13 promot

219 Reduced SIRT1 activity and levels during osteoarthritis (OA) pro

220 ulation of FOXM1 ubiquitination and reducing SIRT1 activity reverses OGT-mediated regulation of FOXM1

221 effects involved oxidative stress reduction, SIRT1-mediated mitochondrial function promotion, and pAK

222 ions in intracellular NAD(+) levels regulate SIRT1 activity, but how SIRT1 enzymatic activity impacts

223 -induced changes in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

224 rtuin1 (SIRT1) and DBC1, which then releases SIRT1 and enhances its deacetylation activity.

225 urther show that caloric restriction rescues SIRT1 levels in transgenic MJD mice, whereas silencing S

226 alpha-secretase (ADAM10), MINT2, FE65, REST, SIRT1, BIN1, and ABCA7, among others.

227 pressed severe ocular disease and restricted SIRT1 cleavage in the periphery, maintaining full-length

228 Remarkably, phosphorylated S164-SIRT1 and CK2 levels were also highly elevated in liver

229 ssion of SIRT1 or a phosphor-defective S164A-SIRT1 mutant promoted fatty acid oxidation and ameliorat

230 ed in mice expressing a phosphor-mimic S164D-SIRT1 mutant.

231 ed animals that received EX-527, a selective SIRT1 inhibitor, displayed exacerbated lung pathology, w

232 ls in transgenic MJD mice, whereas silencing SIRT1 is sufficient to prevent the beneficial effects on

233 We propose that the regulation of Sir2/SIRT1 by acute inebriation forms part of a transcription

234 es histone acetylation, and the sirtuin Sir2/SIRT1 that deacetylates histones and transcription facto

235 Mice with intestinal deletion of SIRT1 (SIRT1 iKO) had abnormal activation of Paneth cells start

236 Mammalian SIRTs (SIRT1-7) differ in their cellular localization and biolo

237 The best-studied sirtuin, SIRT1, counteracts aging- and obesity-related diseases b

238 Sirtuin1 (SIRT1) deacetylase delays and improves many obesity-rela

239 petes with the interaction between sirtuin1 (SIRT1) and DBC1, which then releases SIRT1 and enhances

240 Sirtuins (SIRT1-7) are NAD-dependent proteins with the enzymatic a

241 syl cyclases (CD38 and CD157), and sirtuins (SIRT1-7).

242 Compared with normal human skin, SIRT1 is downregulated in both AD and non-AD lesions.

243 In mouse skin, SIRT1 is haploinsufficient for UVB-induced DNA damage re

244 Epidermis-specific SIRT1 ablation causes AD-like skin lesions in mice, and

245 Using mice with epidermis-specific SIRT1 deletion, we show that SIRT1 is required for effic

246 he rational design of new substrate-specific SIRT1 modulators.

247 an important activation role by stabilizing SIRT1/peptide interactions in a substrate-specific manne

248 Upon energy starvation, SIRT1 interacts with and deacetylates PABP1 and deactiva

249 the importance of maintenance of a suitable SIRT1 dosage for metabolic and tissue homeostasis, which

250 ocyte hyperplasia phenotype, confirming that SIRT1 controls adipocyte hyperplasia through c-Myc regul

251 Here, we demonstrate that SIRT1 dose-dependently regulates cellular glutamine meta

252 We proceeded to demonstrate that SIRT1 induction causes the deacetylation and activation

253 We also demonstrate that SIRT1 is a key regulator of proliferation in preadipocyt

254 The results demonstrate that SIRT1 is a member of, and can regulate, the HPV16 replic

255 Together, these results demonstrate that SIRT1 plays an essential role in the NAc in regulating m

256 We demonstrate that SIRT1-deficient mESCs are hypersensitive to methionine r

257 s provide in vivo and in vitro evidence that SIRT1 in the epidermis regulates cell migration, redox r

258 Here, we provide evidence that SIRT1, the most conserved mammalian NAD(+)-dependent pro

259 More generally, we found that SIRT1 inhibition down-regulates metabolic pathways, incl

260 iny neurons (MSNs) in the NAc, we found that SIRT1 promotes depressive-like behaviors only when overe

261 ays, allow us to propose the hypothesis that SIRT1 may actually play a crucial causal role in overloa

262 These data indicate that SIRT1 is a negative regulator of MMP13 expression, SIRT1

263 tivates its expression, but we observed that SIRT1 repressed LEF1 protein and mRNA expression, ultima

264 f the HPV31 life cycle; here, we report that SIRT1 can directly regulate HPV16 E1-E2-mediated DNA rep

265 ng with the well-known regulatory roles that SIRT1 plays in modulating both anabolic and catabolic pa

266 We now show that SIRT1 activation fails to clinically suppress severe TNF

267 Here, we show that SIRT1 determines the nuclear organization of protein-bou

268 dermis-specific SIRT1 deletion, we show that SIRT1 is required for efficient wound healing.

269 Moreover, we show that SIRT1 levels are required for OGT-mediated regulation of

270 ell Stem Cell, Ryall et al. (2015) show that SIRT1, a NAD(+)-dependent histone deacetylase, acts as a

271 sed K48 polyubiquitination also suggest that SIRT1 could be involved in the catabolic process of hype

272 These observations suggest that SIRT1 phosphorylation modulates the distribution of repl

273 These results suggest that SIRT1 plays an essential role in regulating mood-related

274 Thus, demonstrating for the first time that SIRT1 represses MMP13 in human OA chondrocytes, which ap

275 The SIRT1 agonist SRT1720 was used to enhance PGC1alpha acti

276 In addition, the SIRT1-PABP1 association is not specific to energy starva

277 g gene editing technology (CRISPR/Cas9), the SIRT1 gene was removed from cervical cancer cells.

278 In contrast, the SIRT1 inhibitor, EX527, significantly enhanced PTH-induc

279 identified a reproducible association of the SIRT1 locus with major depression in humans.

280 hibitor, highlighting the involvement of the SIRT1/AMPK pathway in the action of DHPs.

281 Here, we report that hCG regulates the SIRT1/FOXO3a axis in hepatocytes, resulting in immune su

282 Treatment with the SIRT1 inhibitor EX-527 confirmed SIRT1's role in the reg

283 Obese mice fed a diet supplemented with the SIRT1-activating molecule resveratrol exhibited increase

284 to decreased PGC-1alpha acetylation through SIRT1 activation.

285 This leads to SIRT1-mediated p53 and histone 3 lysate 56 deacetylation

286 ced O-GlcNAcylation in cancer cells leads to SIRT1-mediated proteasomal degradation of oncogenic tran

287 SIRT1 in podocytes and that puerarin led to SIRT1-mediated deacetylation of NF-kappaB and suppressio

288 ink between the two processes in relation to SIRT1 function is not clear.

289 reased PARP1 activity may be able to trigger SIRT1-induced circadian phase advancements by decreasing

290 iche secrete cyclic ADP ribose that triggers SIRT1 activity and mTORC1 signaling in neighboring ISCs.

291 ed to generate C33a clones with undetectable SIRT1 expression and lack of SIRT1 elevated E1-E2 DNA re

292 -dependent kinase 2 (CDK2) is activated upon SIRT1 reduction.

293 ted proliferation of breast cancer cells via SIRT1 mediated pathway.

294 nexpected mechanism for SIRT3 regulation via SIRT1-mediated deacetylation.

295 ferentiated adipocytes are hyperplastic when SIRT1 is knocked down stably in mouse 3T3-L1 preadipocyt

296 by deacetylating many proteins, but whether SIRT1 has a role in deacetylating and altering the funct

297 s, and thus offer a novel mechanism by which SIRT1 expression within the hippocampus is suppressed du

298 d may be dependent upon the context in which SIRT1 activity is altered, and the role of SIRT1 in tumo

299 racetylated in aged and obese mice, in which SIRT1 activity is low, and SIRT3 acetylation at Lys(57)

300 was reduced in chondrocytes transfected with SIRT1 siRNA or treated with nicotinamide (NAM), a sirtui